Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Halozyme Therapeutics, Inc.    HALO

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Halozyme Therapeutics, Inc. : Halozyme to Host First Quarter 2012 Financial Results Conference Call

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 10:20pm CET

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com

SOURCE Halozyme Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HALOZYME THERAPEUTICS, INC
11/21 HALOZYME THERAPEUTICS : Provides Update On AbbVie Collaboration
11/17 HALOZYME THERAPEUTICS : Announces Broad Clinical Collaboration Agreement To Eval..
11/17 HALOZYME THERAPEUTICS : Reports Third Quarter 2016 Financial Results
11/10 HALOZYME THERAPEUTICS : Announces Broad Clinical Collaboration Agreement To Eval..
11/08 HALOZYME THERAPEUTICS INC. : (HALO) is Trading Higher on Unusual Volume for Nove..
11/07 HALOZYME THERAPEUTICS : reports 3Q loss
11/07 HALOZYME THERAPEUTICS : Management's Discussion and Analysis of Financial Condit..
11/07 HALOZYME THERAPEUTICS INC : Results of Operations and Financial Condition (form ..
11/07 HALOZYME THERAPEUTICS : Reports Third Quarter 2016 Financial Results
11/03 HALOZYME THERAPEUTICS : FDA Accepts Genentech's Biologics License Application Fo..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/21 AbbVie backs out of development of Halozyme's ENHANZE and TNF; HALO down 10% ..
11/15 Halozyme Is A Core Biotech Buy
11/10 Halozyme and Roche team up assessing drug combo in range of cancers
11/07 Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2016 Results - Earnings ..
11/07 Halozyme Therapeutics, Inc. 2016 Q3 - Results - Earnings Call Slides